Innovative Health Initiative (IHI)

**Overview**
The Innovative Health Initiative (IHI) builds on the successes of, and lessons learnt from, Innovative Medicines Initiative (IMI). IHI contributes to a number of European policies, most notably Europe’s Beating Cancer Plan, the new Industrial Strategy for Europe and the Pharmaceutical Strategy for Europe.

**Goal**
The goal of IHI is to help creating an EU-wide health research and innovation ecosystem that facilitates the translation of scientific knowledge into tangible innovations. These innovations should be safe, effective, people-centred and cost-effective, and cover prevention, diagnostics, treatment and disease management.

**Eligibility**
For the 2023 calls and till further notice, Swiss participants are included in projects as “Associated Partners” (APs) from a non-associated third country. If the proposal is successful, eligible costs of the Swiss entities are in principle reimbursed by the Swiss State Secretariat for Education, Research and Innovation (SERI). In one-stage calls Swiss entities do not contribute toward the in-kind contributions’ percentages (either IKOP or IKAA).

**IHI Partners**
The ‘public’ partner of IHI is the European Union, through the European Commission (EC). The IHI industry partners are COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. Other organisations that want to support specific areas of research without becoming full members of IHI can apply to become ‘contributing partners.’

**Financial Support**
The total budget proposed for IHI is EUR 2.4 billion, half of it contributed by the EC.

**In-Kind contributions**
IHI 1-stage calls requires a certain amount of IKOP and IKAA contributions. The rule is that 45% in-kind contribution needs to be provided by the partners from the 5 IHI industry partner organizations (EFPIA, COCIR, EuropeBio, MedTech Europe and Vaccine Europe) but the Swiss entities’ contribution DOES NOT count toward this percentage. Further Information can be found here.